I'm always hesitant to detract from news about OBJ's BodyGuard project but I think the market are yet to fully understand the significant potential with this initiative. Perhaps the next 12 months will better highlight an unmet need and the gap in the musculoskeletal injuries market to be exploited without competition.
When the market comes to understand this potential for marketing a unique product platform beyond a single partner global distribution network with the value-add proposition to the sporting market for example such as major athletic shoe manufacturers like, Nike, Adidas, Reebok, and/or Puma etc, we may then see some value appreciation.
Think about what consumers of athletic shoes may be looking for and what these global brands are striving to achieve - the answer should probably be the same, and although I'm no athlete, I imagine for those who are, the need for performance enhancement would be at the top of the list...
Nike would undoubtedly have some interest in offering product line extensions to compliment its latest performance enhancing innovations...?
Question of the day: Did this BodyGuard announcement represent the 'stuff' that Jeff thinks we will be very happy with and that OBJ will be very very keen to announce as soon as they possibly can?
2013 AGM Presentation
Procter & Gamble
Following completion of a clinical study into the effect of OBJ’s magnetic microarray technology, P&G and OBJ are in negotiation...
Coty/Philosophy
Philosophy completed a large clinical efficacy study using OBJ’s powered technology during 2013. In response to the outcomes, Philosophy and OBJ are currently negotiating...
GSK Pharmaceuticals
Completion of the Phase 1 optimization program under the GSK Collaboration Agreement using OBJ’s Field-in-Motion technology has resulted in negotiations...
The word of the day should've probably been, 'sequential'
I continue to speculate that P&G will provide the first of the big 'stuff' but it's hard to ignore the fact that the company likes to talk about the dermaportation and or e-Skin patents whenever the name, Coty/Philosophy is mentioned...
Appendix 4E
During the period, the Company announced testing of applications for the dermaportation technology with Coty cosmetic applications. The Company also gained patent protection for dermaportation in both the European and US regions during the period.
2013 Annual Report
Letter to shareholders - Glyn Denison
In addition, during the year the Company announced testing of applications for the dermaportation technology with Coty cosmetic applications. The Company also gained patent protection for dermaportation which is being evaluated by Coty in both the European and US regions.
Operations Review - Jeff Edwards
During the period, the Company announced its collaboration with the Coty Group’s prestige cosmetic skincare company Philosophy. That collaboration is based around the Company’s powered technology and the e-Skin platform that includes an e-commerce component. Progress with Coty has been rapid...
... then on the same day of the AGM presentation release (not marked price sensitive) came a 'Patent Portfolio Update' announcement about a new patent being filed locally, which was presumably considered to be, 'Price Sensitive' - or rather, perhaps the sensitive part only applied to the separate news provided in the last sentence of that announcement which coincidentally omitted any mention of Coty/Philosophy...;)
PATENT PORTFOLIO UPDATE
OBJ Limited advises that its wholly-owned subsidiary, International Scientific Pty Ltd (“ISPL”) has lodged an Australian Provisional Patent Application entitled “Method and Apparatus for Increased Partitioning of Agents into the Stratum Corneum”.
This third magnetic enhanced delivery technology by OBJ is known as Enhanced Partitioning and Penetration System” or “EPPS”. The new technology utilises synchronized time varying magnetic fields in unison with microvibrational
energy to increase the rate of ingredient partitioning from a formulation and increases diffusion into the upper skin layers (stratum corneum) that are the primary target for cosmetic and skin care products.
OBJ’s E-Skin technology patent has now been lodged internationally as a final specification under the Patent Cooperation Treaty (PCT).
Kind of off topic, but maybe not - Genzyme, one of the world’s leading biotechnology companies and a global leader in cell-based therapies and regenerative medicines boasting innovative solutions for unmet medical needs, handed over the keys to its world class state-of-the-art production facilities for a song to the other company I'm invested in yesterday. The facility which was only built in 2009 was to manufacture the next generation of an autologous cellular product called, Carticel - the first and only FDA-approved cell therapy product that is used to repair articular cartilage injuries in the knee of adults.
It's hard to imagine why Genzyme, or parent company, Sanofi would be running for the hills in relation to its next generation of invasive surgery to repair knee cartilage... Perhaps they heard something about a unique and highly advanced joint treatment product platform that won't require any surgery?
(20min delay)